Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | LY3405105 |
| Synonyms | |
| Therapy Description |
LY3405105 is a CDK7 inhibitor, which induces cell cycle arrest, apoptosis, and inhibits transcription (PMID: 32385714). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| LY3405105 | LY-3405105|LY 3405105 | CDK7 Inhibitor 16 | LY3405105 is a CDK7 inhibitor, which induces cell cycle arrest, apoptosis, and inhibits transcription (PMID: 32385714). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT03770494 | Phase I | LY3405105 | A Study of LY3405105 in Participants With Advanced Cancer | Terminated | USA | FRA | ESP | CAN | 1 |